GLP-1 Side Effects: What Every Functional Medicine Practitioner Must Know

She lost 40 pounds and everyone thinks it’s amazing.

And I get it. She’s been fighting her weight for years and is tired of trying. She’s exhausted with the whole thing. She’s been told to eat less and exercise more so many times that she stopped believing that was the answer. So she said yes to the drug, the weight came off, and now she feels amazing and is getting compliments everywhere she goes.

But here’s what we see. She’s constipated. She’s tired. She looks a little gaunt, a little frail. Her arms are floppier than they used to be. She’s still not eating much because she’s too scared to gain back the weight. And her metabolism? It’s a train wreck. Not even close.

The GLP-1 conversation is everywhere right now, and I’m not here to debate whether your patient should be on one. That decision belongs to her and her prescribing doctor. What I am here to talk about is what’s actually happening physiologically when she’s on one of these drugs, and what you as a functional medicine practitioner need to be watching for and doing to protect her while she’s on it.

Because if you’re not asking these questions, nobody else is.

How GLP-1 Drugs Actually Work (And Why the Same Mechanism That Helps Also Hurts)

GLP stands for glucagon-like peptide. It’s an incretin hormone that the body naturally produces from L-cells in the intestine in response to food. In normal physiology, GLP helps coordinate communication between the gut, pancreas, brain, stomach, and liver. It helps the pancreas release insulin, suppresses glucagon, slows gastric emptying to blunt post-meal glucose spikes, and sends satiety signals to the brain.

All of that is normal. What these drugs do is amplify and prolong that signal pharmacologically. Instead of a short-lived meal-related response, your patient now has a much stronger, longer-lasting incretin signal affecting appetite, satiety, and pancreatic function.

In practice, this means four things: more insulin secretion, suppressed glucagon, suppressed appetite (what the researchers call reduced ‘food noise’), and significantly slowed gastric emptying and motility.

That last one is the one I want you to really sit with. Slowed gastric motility. Because the same thing that makes the drug work is exactly what creates the problems you’re going to be managing.

What Are the GLP-1 Side Effects Practitioners Actually Need to Watch For?

GLP-1 drugs cause four main physiological problems for patients: slowed gastric motility leading to gastroparesis-type symptoms, gallbladder stasis that increases stone and sludge risk, potential thyroid C-cell changes, and significant lean muscle mass loss. Functional medicine practitioners can support patients by protecting digestion, providing consistent bile support, monitoring key labs, and building metabolic infrastructure before the patient stops the medication.

Problem 1: Gastroparesis-Type Symptoms and Digestive Breakdown

When gastric emptying slows, food sits in the stomach longer. Your patient feels full faster and stays full longer, so she eats less. That’s the mechanism for weight loss. But it’s also the mechanism for nausea, bloating, constipation, vomiting, reflux, food aversions, and dehydration.

For patients who already had sluggish digestion, a history of reflux, poor vagal tone, or low protein intake before starting, this is a particularly bad option. You’re putting metabolic brakes on a system that was already struggling.

The red flags to watch: persistent vomiting, inability to tolerate a normal meal volume, progressive constipation, visible abdominal distension, electrolyte shifts on bloodwork, and signs of malnutrition. When you see those, this is not a moment to toss digestive enzymes at her and call it a day. Point her back to her prescribing doctor.

Problem 2: Gallbladder Stasis and Bile Risk

Gallbladder, gallbladder, gallbladder. I cannot say this enough. Rapid weight loss already increases gallstone risk because when fat is metabolized quickly, the liver secretes more cholesterol into bile, making it more lithogenic. Add to that the fact that GLP-1 drugs can reduce gallbladder motility through disrupted cholecystokinin signaling, and you have a setup for bile sludge or stone formation.

A large meta-analysis found that GLP-1 use was associated with increased risk of gallbladder and biliary disease, especially at higher doses and longer duration. Are the prescribing doctors telling patients this? In my experience, usually not.

Every single patient on a GLP-1 needs gallbladder support. This is non-negotiable. Watch for light-colored stools, dark urine, right upper quadrant pain after meals, nausea, or pain radiating to the right shoulder blade. All of them are gallbladder red flags.

Problem 3: Thyroid C-Cell Risk

This one requires nuance. The thyroid warning on GLP-1 drugs is based primarily on rodent data showing elevated thyroid C-cell tumor risk, specifically medullary thyroid carcinoma from the parafollicular C cells. The human data is more complicated because human cells appear to be less responsive to GLP receptor stimulation than rodent cells.

That said, the warning is still there and the drugs are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma. If you have a patient on a GLP who’s never been asked about this, ask the question. Informed consent is not optional.

Problem 4: Lean Muscle Mass Loss and Weight Rebound

This is the one that should stop someone in their tracks. 

When appetite decreases and total food intake is less than before, protein intake drops too. When the body is calorie and protein deficient, gluconeogenesis kicks in and starts cannibalizing muscle to reach its metabolic baseline. Add the fact that GLP-1 drugs cause reduced energy levels leaving patients less motivated to strength train, and it’s a not-so-perfect storm.

If a woman loses 40 pounds, a huge portion of that is muscle mass. That can’t be counted as a win. Especially not for women in perimenopause or menopause, who are already losing muscle as a natural part of aging. Muscle influences resting metabolic rate. Muscle supports insulin sensitivity. Muscle is one of the most important things we protect for longevity. And we’re prescribing the very thing that takes it away.

Make it make sense.

And then there’s the rebound. Research has shown that after stopping semaglutide, patients regained approximately two-thirds of the body weight they had previously lost within one year after stopping treatment. If she loses 40 pounds, she’s gaining back 25 to 30. Because the drug didn’t build any metabolic infrastructure. It just suppressed the signal.

How Do You Support a Patient Who Is Already on a GLP-1?

First, no judgment. That is not our job. Your job is to ask the questions nobody else is asking.

What are you doing about protein intake? How are you managing muscle mass? Are you doing any strength training? Do you feel weaker, more fatigued? Are you constipated? Those are the conversations that need to happen sooner than later.

Then, from a clinical support standpoint:

Protect digestion. Use HCl support, bitters, digestive enzymes. Keep that gastric pH moving. Keep the upper digestive system as active as possible. Do not let it go idle.

Protect the gallbladder. Pick your bile support and keep her on it indefinitely. This ensures bile continues to move and does not become stagnant. 

Be intentional about nutrient intake. She may have defaulted to crackers, cheese, and an apple because that’s all she can tolerate. Gently, practically, help her get some fat and color and protein into whatever she is eating. This is essential.

Keep an eye on fasting glucose, fasting insulin, A1C, triglycerides, liver enzymes, CRP, and thyroid markers. Have her keep a food diary so you can both see what’s actually going in. Watch for signs of food aversion or possible eating disorder. Refer out early if needed.

Your goal is to build up her reserves while she’s losing the weight. This enables her body to better respond when she comes off the medication. She’ll already have improved eating habits, comfortable eating more protein and able to maintain steady blood sugar. 

If you don’t do that work now, she’s going to end up with less muscle, poorer metabolic reserve, more fear around food, and two-thirds of the weight coming right back.

The Bigger Picture: Skinny Is Not the Finish Line

If there’s one thing I want you to take from this episode, it’s that being thinner is not the same as being healthier. The same mechanism that makes these drugs effective is what makes them dangerous over the long term. 

You are uniquely positioned to be the practitioner who stands in that gap and asks the questions no one else has: What does your transition off the GLP-1 look like? How is your relationship with food now – and what will that look like on the other side of this?

When you start asking these questions, especially to women in perimenopause, menopause, post-menopause, you can prevent the metabolic train wreck from happening. Instead, you can offer something that improves their overall health instead of just moving the number on the scale.

If you want a clear, structured framework for addressing the foundational clinical pillars with every patient, regardless of whether they’re on a GLP-1 or not, go grab my free guide, The 5 Clinical Non-Negotiables.

This is the place I always start. Once you know what to focus on first, it will make everything else you do work better.